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HIV-1 latency in resting CD4
þ T cells represents a major barrier to virus eradication in patients on highly active
antiretroviral therapy (HAART). We describe here a novel post-transcriptional block in HIV-1 gene expression in resting
CD4
þ T cells from patients on HAART. This block involves the aberrant localization of multiply spliced (MS) HIV-1 RNAs
encoding the critical positive regulators Tat and Rev. Although these RNAs had no previously described export defect,
we show that they exhibit strict nuclear localization in resting CD4
þ T cells from patients on HAART. Overexpression of
the transcriptional activator Tat from non-HIV vectors allowed virus production in these cells. Thus, the nuclear
retention of MS HIV-1 RNA interrupts a positive feedback loop and contributes to the non-productive nature of
infection of resting CD4
þT cells. To define the mechanism of nuclear retention, proteomic analysis was used to identify
proteins that bind MS HIV-1 RNA. Polypyrimidine tract binding protein (PTB) was identified as an HIV-1 RNA-binding
protein differentially expressed in resting and activated CD4
þ T cells. Overexpression of PTB in resting CD4
þ T cells
from patients on HAART allowed cytoplasmic accumulation of HIV-1 RNAs. PTB overexpression also induced virus
production by resting CD4
þT cells. Virus culture experiments showed that overexpression of PTB in resting CD4
þT cells
from patients on HAART allowed release of replication-competent virus, while preserving a resting cellular phenotype.
Whether through effects on RNA export or another mechanism, the ability of PTB to reverse latency without inducing
cellular activation is a result with therapeutic implications.
Citation: Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF (2006) Nuclear retention of multiply spliced HIV-1 RNA in resting CD4
þ T cells. PLoS Pathog 2(7): e68. DOI: 10.
1371/journal.ppat.0020068
Introduction
Treatment of HIV-1-infected individuals with highly active
antiretroviral therapy (HAART) can reduce plasma virus
levels to below the limit of detection of ultra-sensitive clinical
assays [1–3]. However, even in the setting of optimal treat-
ment, replication-competent HIV-1 persists in resting CD4
þ
T cells [4–8] and possibly in other viral reservoirs (reviewed in
[9]). Resting CD4
þ T cells from patients on HAART do not
spontaneously produce HIV-1 unless activated [4,10]. How-
ever, following activation of these cells, replication-compe-
tent HIV-1 can be invariably recovered even from patients
who have had suppression of viremia on HAART for as long
as seven years [11,12]. Taken together, these results demon-
strate that a stable state of latent infection can be established
in resting CD4
þ T cells. The latent reservoir has an extremely
slow decay rate [11–15] that will likely preclude virus
eradication unless novel approaches [16–23] can purge
latently infected cells. Of particular interest are strategies
that would induce latent HIV-1 without causing global T-cell
activation [20]. The design of such strategies requires an
understanding of the molecular mechanisms of latency.
Resting CD4
þT cells from infected individuals contain rare
cells with integrated HIV-1 DNA [4,5,24], and these cells are
presumed to represent the stable latent reservoir, since most
studies indicate that unintegrated forms of HIV-1 DNA are
labile [25–28]. Among cells with integrated HIV-1 DNA, only
a small fraction can be induced to release replication-
competent virus following cellular activation [5]. The rest
contain defective or permanently silenced viral genomes.
Mechanistic studies of latency are thus complicated by the
fact that latently infected cells (cells capable of releasing
replication-competent virus) represent only a small fraction
of the cells carrying HIV-1 DNA, which in turn represent only
a small fraction of the resting CD4
þ T cell population.
Mechanistic studies of HIV-1 latency must be interpreted
with these caveats in mind. Because of the difﬁculties
involved in the analysis of HIV-1 latency in vivo, many
mechanistic studies have been carried out in cell line systems
that may not precisely reﬂect the physiology of the
profoundly quiescent cells that harbor latent HIV-1 in vivo.
Most of the proposed mechanisms for HIV-1 latency
operate at the level of transcription. These include proviral
integration into sites that are repressive for transcription
[29–32], DNA and histone modiﬁcations that inhibit tran-
scription [33,34], the absence of host transcriptional activa-
tors necessary for HIV-1 gene expression [35–39], the
presence of transcriptional repressors [34,40], transcriptional
interference [32,41,42], and the premature termination of
HIV-1 transcripts due to the absence of the viral protein Tat
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transcriptional elongation [43–47]. There are clearly major
defects in transcriptional initiation and elongation in resting
CD4
þ T cells [21,44,48,49], and processive HIV-1 transcripts
are difﬁcult to detect in these cells [50,51].
In addition to these mechanisms affecting transcription,
post-transcriptional mechanisms may also contribute to
latency. With extremely sensitive methods, some processive
transcripts, including both unspliced (US) and multiply
spliced (MS) HIV-1 mRNAs, have been demonstrated in
resting CD4
þT cells from infected individuals [10,49]. Despite
the presence of these transcripts, no virus is produced. This
could reﬂect deﬁcient nuclear export of incompletely spliced
HIV-1 RNAs in the absence of the viral protein Rev [52,53].
Interestingly, Rev and the transcriptional activator Tat, are
both products of MS HIV-1 RNAs, which have no known
export defect. An absence of each of these viral proteins has
been implicated in latency [21,47,52,53]. Tat acts at the level
of transcription elongation to promote high level tran-
scription from the HIV-1 long terminal repeat (LTR)
[43,46,54,55], while Rev promotes export of incompletely
spliced viral HIV-1 RNAs to the cytoplasm [56–59]. In cells
from patients on HAART, exogenous Tat has been shown to
promote positive feedback upregulation of HIV-1 gene
expression in cells from infected individuals [21], and a
recent study in infected cell lines has shown that stochastic
ﬂuctuations in Tat activity can lead to large differences in the
levels of HIV-1 gene expression [47]. Given the presence of
MS HIV-1 mRNAs encoding Tat and Rev in resting CD4
þ T
cells [49], it has been unclear why positive feedback does not
increase virus gene expression to levels sufﬁcient for virus
production. We describe here a post-transcriptional block in
the export of MS HIV-1 RNA that may prevent this positive
feedback loop. In addition, we identify a host protein which,
when overexpressed in resting CD4
þ T cells, can reverse
latency without inducing cellular activation.
Results
Nuclear Localization of MS HIV-1 RNA in Resting CD4
þ T
Cells
In vivo, latent viral genomes are found in G0 resting
memory CD4
þ T cells [5,60]. Because latency may involve
aspects of the unique physiology of these profoundly
quiescent cells, it is best analyzed using primary resting
CD4
þ T cells from infected individuals rather than trans-
formed cell lines. However, the analysis of latency in primary
cells is complicated by the fact that only a small fraction of
the cells harboring HIV-1 DNA in vivo can be induced to
produce infectious virus upon cellular activation [5]. The
remaining cells may carry defective viruses. In the molecular
analysis of HIV-1 DNA or RNA species in primary cell
populations, it is not generally possible to distinguish
replication-competent from defective forms. Replication-
competence can only be established in separate virus
outgrowth experiments. By combining data from these two
approaches, inferences can be made about the biology of the
small subpopulation of cells that harbor replication-compe-
tent virus.
We ﬁrst analyzed the distribution of the bulk population of
HIV-1 RNA molecules in highly puriﬁed populations of
resting CD4
þ T cells from patients on suppressive HAART
regimens. Both MS and US HIV-1 mRNAs can be detected in
these cells with sensitive methods [49]. To understand why the
presence of MS HIV-1 mRNA does not lead to Tat-mediated
positive feedback ampliﬁcation of virus gene expression and
virus production, we ﬁrst examined the subcellular local-
ization of HIV-1 RNA in resting CD4
þ T cells. Nuclear,
cytoplasmic, and total RNA fractions were isolated from
resting CD4
þ T cells, and an ultra-sensitive hemi-nested RT-
PCR was performed on each fraction. US HIV-1 mRNAs,
which have an export defect in the absence of high levels of
the HIV-1 Rev protein [52,53], were retained in the nucleus of
these cells (Figure 1A). Surprisingly, MS HIV-1 mRNAs, not
previously known to have an export defect, were also
exclusively nuclear in localization (Figure 1A). The same
result was observed in ten patients; both US and MS HIV-1
RNAs were detected only in the nuclear fraction of primary
resting CD4
þ T cells.
Unspliced and spliced glyceraldehhyde-3-phosphate dehy-
drogenase (GAPDH) mRNAs were also ampliﬁed from these
fractions in order to determine the quality of the nuclear-
cytoplasmic separation, as well as the integrity of the isolated
RNA (Figure 1A). As expected, unspliced GAPDH RNA was
localized to the nucleus while the majority of spliced GAPDH
mRNA was localized to the cytoplasm of resting CD4
þ T cells.
This conﬁrms the efﬁcacy of the cell fractionation, and
further demonstrates that the aberrant localization of HIV-1
RNA is not due to a global defect in RNA export in these cells.
Whether the RNA localization patterns observed in bulk
populations of resting cells from infected donors are
characteristic of the tiny fraction of cells harboring latent,
replication-competent HIV-1 genomes cannot be determined
from this analysis.
To determine whether nuclear localization of HIV-1 RNA
is altered in response to T-cell stimulation, puriﬁed resting
CD4
þ T cells were activated with anti-CD3/anti-CD28 for
various times and then fractionated. Both MS and US HIV-1
RNAs were localized exclusively to the nucleus until 48 to 72
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Synopsis
HIV-1 has the ability to establish a state of latent infection in resting
memory CD4
þT cells. These latently infected cells represent a stable
reservoir for the virus that is a major barrier to viral eradication.
Understanding how this reservoir is established, maintained, and
reactivated is essential for developing methods to target and
eliminate these cells. Currently, many proposed mechanisms of HIV-
1 latency involve a dramatic reduction in ongoing HIV-1 tran-
scription. However, some HIV-1 mRNAs are made, and it has been
unclear why the cells are unable to produce virus. This study
describes the surprising observation that mRNAs encoding the viral
regulatory proteins Tat and Rev are retained in the nucleus of
infected resting CD4
þ T cells. A cellular HIV-1 RNA-binding protein
called polypyrimidine tract binding protein was shown to reverse
latency when overexpressed in resting CD4
þ T cells. This over-
expression of polypyrimidine tract binding protein was sufficient to
allow release of replication-competent HIV-1 from latently infected
cells without inducing cellular stimulation. These experiments
suggest that multiple factors contribute to the maintenance of
HIV-1 latency in vivo; however, perturbation of the level of a specific
cellular protein is sufficient to overcome these blocks and allow for
virus production.h following stimulation when cytoplasmic HIV-1 RNAs were
detected (Figure 1B). The appearance of HIV-1 RNA in the
cytoplasm preceded the release of virus particles into the
supernatant by 24–48 h [49].
Identification of MS HIV-1 RNA-Binding Proteins in Resting
and Activated CD4
þ T Cells
The aberrant nuclear localization of MS HIV-1 mRNAs in
resting CD4
þ T cells could be due to the presence of a
negative regulator or the absence of a positive export factor.
Primary resting and activated CD4
þ T cells were therefore
screened for factors that bind speciﬁcally to a minimal MS
HIV-1 RNA (Figure S1A). Candidate HIV-1 RNA-binding
proteins were then identiﬁed by PAGE-mass spectrometry
(Figure S1B). This screen identiﬁed a number of known RNA-
binding proteins, including several which have been pre-
viously shown to bind HIV-1 RNA. One of these was
polypyrimidine tract binding protein (PTB). PTB plays a role
in post-transcriptional regulation of gene expression (re-
viewed in [61]). For example, PTB is involved in post-
transcriptional regulation of gene expression in response to
T-cell stimulation [62–64]. PTB has been previously shown to
associate with HIV-1 RNA [65]. The role of PTB in HIV-1
gene expression has not yet been deﬁned.
To examine the speciﬁcity of PTB binding to HIV-1 RNA,
recombinant PTB was incubated with in vitro-transcribed,
biotinylated MS HIV-1 RNA bound to streptavidin-conju-
gated magnetic beads (Figure S1A). Recombinant PTB
bound MS HIV-1 RNA and was released upon RNase
digestion (Figure 2A). The binding was blocked by pre-
incubation of PTB with increasing amounts of non-biotiny-
lated MS HIV-1 RNA. Binding of PTB decreased progres-
sively with increasing ratios of non-biotinylated to
biotinylated MS HIV-1 RNA. PTB binding was not decreased
by a 5-fold mass excess of total yeast RNA, a non-speciﬁc
competitor (Figure 2A).
To determine whether differences in PTB levels in resting
and activated CD4
þ T cells might be involved in the observed
export defect, we ﬁrst measured steady-state levels of PTB
protein in puriﬁed primary resting CD4
þ T cells and
phytohemagglutinin (PHA)-stimulated, activated CD4
þ T
cells. Quantitative Western analyses indicated that PTB
expression increases by at least 4.5-fold upon cell stimulation
(Figure 2B). PTB has four known isoforms generated by
alternative splicing. Three variants produce bands of 57–59
kDa, while the fourth variant of PTB has an apparent
molecular weight of 25 kDa. Only the larger isoforms were
upregulated following cellular stimulation, while total levels
of the 25-kDa isoform (PTBT) decreased upon cellular
stimulation (Figure 2B).
PTB Overexpression Is Sufficient to Cause Virus Production
by Resting CD4
þ T Cells from Infected Individuals
The direct binding of PTB to MS HIV-1 RNA, and the
differential regulation of PTB isoforms with T-cell stimula-
tion, suggested that PTB might act as a positive factor for
HIV-1 gene expression. To test this hypothesis, we generated
expression constructs for various forms of PTB (Figure 3A).
These included full-length PTB and a mutant form of full-
length PTB with a serine to alanine mutation in the nuclear
export signal (PTB ser-ala). The N-terminal 55 residues of
PTB contain a nuclear localization signal (NLS). PTB ser-ala
has a single serine to alanine substitution at position 16 in the
nuclear export signal that is also located in this region. This
mutation dramatically reduces nucleo-cytoplasmic shuttling
of PTB but does not alter nuclear import [66]. We also
generated an expression vector for PTBT, the 25-kDA
isoform, which lacks an NLS but contains two intact RNA
recognition motifs that allow it to interact with cognate RNAs
as efﬁciently as full-length PTB does [64].
Resting CD4
þ T cells from patients on HAART were
transfected with empty vector, PTB, PTB ser-ala, or PTBT
using an Amaxa Nucleofector. At 72 h post-transfection, an
ultra-sensitive RT-PCR assay was employed to detect the low
levels of virions released into the supernatants of these
cultures. In cells transfected with empty vector or PTBT, the
Figure 1. Both MS and US HIV-1 RNAs Localize to the Nucleus of Resting CD4
þ T Cells from Patients on HAART
(A) RT-PCR analysis of US and MS HIV-1 RNAs in nuclear (N), cytoplasmic (C), and total (T) RNA fractions isolated from 10
6 purified resting CD4
þ T cells
from a patient on HAART. Unspliced GAPDH and spliced GAPDH were used as internal controls for fraction purity and RNA integrity.
(B) Effect of cellular activation on the localization of HIV-1 RNAs. 10
6 resting CD4
þ T cells were stimulated with anti-CD3 and anti-CD28. Nuclear (N),
cytoplasmic (C), and total (T) RNA fractions were isolated at given times post-activation and analyzed as above with primers to detect US (shown) and
MS (not shown) HIV-1 RNAs. Similar results were obtained with both US and MS primer sets.
DOI: 10.1371/journal.ppat.0020068.g001
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RNA Trafficking and HIV Latencyamount of virus released was often below the limit of
detection (,50 copies of HIV-1 RNA/ml), although occasion-
ally a mock-treated sample would yield a very low-level
positive value for HIV-1 RNA (Figure 3B). Because an
undetectable viral RNA measurement could represent low
levels of virus production and not an actual zero, we
considered an undetectable viral load as equivalent to 50
copies/ml when calculating release. The low positive values
may represent non-speciﬁc stimulation due to in vitro
culture. Cells transfected with PTB or PTB ser-ala showed a
dramatic (100- to 10,000-fold) upregulation of virus produc-
tion (Figure 3B). The stimulation of HIV-1 production by
PTB transfection was consistently observed in all ﬁve patients
tested. Although these results do not establish that the virions
released are infectious, they do show that PTB overexpression
can induce infected resting CD4
þ T cells to produce and
release virus particles. To determine if the observed
upregulation of virus production was speciﬁc to PTB, other
HIV-1 RNA-binding proteins identiﬁed in the proteomic
screen were overexpressed in resting CD4
þ T cells. Cells
transfected with hnRNPA1 or La, other host proteins capable
of binding HIV-1 RNA [65,67,68], did not upregulate viral
gene expression (Figure 3C).
PTB Expression Specifically Upregulates HIV-1 Gene
Expression without Inducing Cellular Activation
To determine if PTB overexpression was inducing virus
production non-speciﬁcally through general effects on the
activation status of the transfected cells, we carefully
evaluated transfected cells for expression of well-established
markers of cellular activation. PTB-transfected resting CD4
þ
T cells did not express the activation marker CD25, and only
a small fraction (3%) of the cells expressed levels of HLA-DR
that were above background (Figure 4A). Following PTB
transfection, there was no detectable upregulation of CD69,
an early activation marker, at 8 h post-transfection (not
shown). In addition, PTB-transfected cells maintained a small,
resting cell morphology as shown by the forward scatter
proﬁles in Figure 4A and by the photomicroscopy (see below).
As a positive control, we showed that expression of CD25 and
HLA-DR were markedly increased by PHA stimulation, as was
cell size (Figure 4A). Additionally, transfected cells remained
in the G0/G1a phase of the cell cycle. Transfected cells were
stained with 7-amino-actinomycin-D/pyronin Y (7AAD/PY) to
evaluate DNA/RNA content and cell-cycle status. As is shown
in Figure 4B, PTB transfection caused no change in DNA
levels and only a slight increase in RNA levels. In contrast,
PHA activation caused a dramatic increase in cellular RNA
levels followed by entry of cells into the cell cycle. Taken
together, these results suggest that overexpression of PTB in
resting CD4
þ T cells can induce virus production without the
wholesale induction of the G0/G1a ! G1b transition that is
associated with increased permissiveness to HIV-1 replication
[69,70].
High Level Expression of Tat or PTB Results in Efficient
Virus Production Comparable to Virus Production by PHA-
Stimulated Resting CD4
þ T Cells
The results presented above suggest that the export block
affecting MS HIV-1 RNAs encoding the Tat and Rev may
contribute to the non-productive nature of HIV-1 infection
of resting CD4
þ T cells by blocking a positive feedback loop
that would result if these RNAs could be translated in the
cytosol. To further test this hypothesis, we bypassed this block
by transfecting resting CD4
þT cells from patients on HAART
with a simple, non-HIV expression vector carrying a Tat
cDNA. Tat expressed in this context caused dramatic (1,000-
fold) upregulation of virus production (Figure 5) that was
even greater than that seen in PTB-transfected cells or in cells
stimulated with the mitogen PHA. This result is consistent
with previous observations that infected resting cells have a
defect in transcriptional elongation [21,44,48,49], and that
this defect can be overcome by Tat [21]. These ﬁndings can
now be reconciled with the observation that resting cells
express MS mRNA for Tat and Rev without producing virus
[49]. Although MS RNAs encoding these positive regulatory
factors are produced at low levels in resting CD4
þT cells, they
are retained in the nucleus, and thus no positive feedback is
possible. This effect is reversed by increased levels of PTB or a
dramatic increase in transcription from the HIV-1 LTR.
Partial Knockdown of PTB in Activated CD4
þT Cells Is Not
Sufficient to Prevent Virus Production
Because overexpression of Tat alone in resting CD4
þT cells
is sufﬁcient to upregulate viral gene expression in infected
resting CD4
þ T cells (Figure 5), we suspected that the export
Figure 2. PTB Binds Specifically to MS HIV-1 RNA and Is Upregulated
upon Cellular Stimulation
(A) PTB binds specifically to MS HIV-1 RNA. Recombinant PTB was pre-
incubated with increasing molar equivalents (0X, 1X, 2X, 5X) of non-
biotinylated MS HIV-1 RNA (relative to biotinylated MS HIV-1 RNA) or a 5-
fold mass excess of non-specific (NS) competitor, total yeast RNA; and
then incubated with biotinylated, in vitro-transcribed MS HIV-1 RNA
bound to streptavidin-conjugated magnetic particles. PTB protein eluted
by RNase digestion was analyzed by Western blot.
(B) PTB expression increases in response to T-cell stimulation. Expression
of PTB was measured by Western blotting in resting CD4
þT cells cultured
for 72 h without activating stimuli ( ) or with (þ) anti-CD3/anti-CD28.
Vinculin served as a loading control.
DOI: 10.1371/journal.ppat.0020068.g002
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þT cells may be saturated and overcome
at high levels of HIV-1 gene expression. Thus, partial short
interfering RNA (siRNA) knockdown of PTB in maximally
activated CD4
þ T cells did not decrease HIV-1 production
(Figure S2). PTB may be overcoming a negative factor
affecting HIV-1 RNA export that is readily saturable or that
is present only in resting CD4
þ T cells.
Nuclear Expression of PTB Is Required for Efficient HIV-1
Gene Expression
Because MS HIV-1 mRNAs have a nuclear export defect in
resting CD4
þ T cells (Figure 1), we hypothesized that only
nuclear forms of PTB could interact with MS HIV-1 mRNA
and facilitate export. Therefore, the nuclear localization of
PTB isoforms was examined in primary resting CD4
þ T cells
by immunoﬂuorescence using an antibody that recognizes all
isoforms. In untransfrected cells, endogenous PTB staining
was largely cytoplasmic (Figure 6, top panels). This result
likely reﬂects the prominence in resting cells of the PTBT
isoform that lacks an NLS and that shows cytoplasmic
localization in other cells [64]. Similarly, in PTBT-transfected
cells, the majority of PTBT was localized to the cytoplasm
(Figure 6, bottom panels). In contrast, cells transfected with
PTB exhibited strong nuclear localization (Figure 6, center
panels). PTB ser-ala, which carries a disrupted nuclear export
Figure 3. PTB Overexpression Is Sufficient to Reverse HIV-1 Latency in Primary Resting CD4
þ T Cells
(A) Diagram of expression constructs. The PTB construct contains full-length PTB including a NLS and four RNA recognition motifs (RRM). PTB ser-ala has
a single serine to alanine substitution at position 16 in the NES located within the NLS region. PTBT is the 25 kDA isoform which lacks an NLS but
contains two intact RRMs.
(B) Overexpression of PTB and PTB ser-ala is sufficient to upregulate virus production from resting CD4
þ T cells. Purified resting CD4
þ T cells from
patients on HAART were transfected with the indicated constructs. Culture supernatants were isolated 72 h post-transfection and analyzed for viral RNA.
Dotted line represents the limit of detection of the assay.
(C) Other cellular proteins that bind HIV-1 RNA cannot induce virus production from resting CD4
þ T cells of patients on HAART. Resting CD4
þ T cells
were transfected as described above with empty vector or hnRNP A1 (left panel) and empty vector or La (right panel). HIV-1 RNA levels in the
supernatants 72 h after transfection are shown.
DOI: 10.1371/journal.ppat.0020068.g003
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RNA Trafficking and HIV Latencysignal, also showed strong nuclear localization. Interestingly,
cells transfected with PTB ser-ala consistently showed the
highest levels of virus production (Figure 3). Taken together,
these results suggest that nuclear localization of PTB is
important for upregulation of virus production by infected
resting CD4
þ T cells.
PTB Overexpression Does Not Increase Total Intracellular
Concentrations of HIV-1 RNA
We next asked how nuclear forms of PTB stimulate virus
production. In other systems, PTB acts post-transcriptionally
through effects on RNA processing and stability [61,62,64].
We measured total steady-state levels of intracellular HIV-1
RNA following transfection of resting CD4
þ T cells from
patients on HAART with PTB or empty vector. PTB trans-
fection had no observed effect on total intracellular HIV-1
RNA levels compared to mock-transfected controls (Figure
7A). PTB has also been shown previously to stabilize certain
cellular RNAs [64]. To examine the possibility that PTB alters
the half-life of intracellular HIV-1 RNAs, we measured the
turnover of HIV-1 RNAs in cells transfected with PTB (Figure
7B). At 24 h post-transfection, a-amanitin was added to cells
to block de novo RNA synthesis. Total RNA was isolated at
given times, and real-time RT-PCR was performed to detect
Figure 4. PTB Expression Specifically Upregulates HIV-1 Gene Expression without Inducing Cellular Activation
(A) Expression of activation markers on PTB-transfected primary resting CD4
þT cells. PTB-transfected cells were analyzed 24, 48 (shown), and 72 h post-
transfection for surface expression of CD25 and HLA-DR. Cells were stained with phycoerythrin-conjugated isotype control antibody, anti-CD25, or anti-
HLA-DR. Cell size is indicated by the forward scatter (FSC) values on the Y-axis.
(B) PTB-transfected cells do not transition to the G1b stage of the cell cycle. Mock-transfected and PTB-transfected cells and PHA-stimulated cells were
stained with PY and 7AAD to measure RNA and DNA levels, respectively. Dye binding was assessed by flow cytometry.
DOI: 10.1371/journal.ppat.0020068.g004
Figure 5. Induction of Virus Production by PTB or Tat
High-level expression of PTB or Tat in resting CD4
þ T cells from patients
on HAART induces virus production that is comparable to that seen
following PHA stimulation. Resting CD4
þT cells purified from patients on
HAART were transfected as described above with expression vectors for
PTB or Tat, or as a positive control, were stimulated with PHA. For all
transfections, supernatant HIV-1 levels were measured at 72 h post-
stimulation. For PHA-stimulated cells, supernatant levels of HIV-1 RNA
were measured every day for a 6-d period. Levels shown reflect peak
virus release over the 6-d period.
DOI: 10.1371/journal.ppat.0020068.g005
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RNA Trafficking and HIV Latencytotal HIV-1 RNAs. Transfection with PTB did not substan-
tially alter the turnover rate of HIV-1 RNAs compared with
mock-transfected controls.
PTB Expression Alters the Subcellular Distribution of HIV-1
RNAs in Resting CD4
þ T Cells In Vivo
The ability of PTB to upregulate virus production without
altering levels of virus gene expression or viral mRNA stability
is consistent with the hypothesis that PTB acts post-tran-
scriptionally in a direct or indirect manner to promote the
export of MS HIV-1 mRNAs. This in turn could permit
synthesis of Tat and Rev proteins, Tat-mediated upregulation
of transcription, and Rev-mediated export of the incom-
pletely spliced HIV-1 mRNAs that encode the structural
proteins needed for virion production. To conﬁrm this
notion, PTB- and mock-transfected cells were fractionated
and assessed for nuclear and cytoplasmic localization of HIV-
1 RNAs. Mock-transfected controls showed exclusive nuclear
localization of HIV-1 RNAs, while cells expressing PTB
accumulated HIV-1 RNAs in the cytoplasm within 48 h
following transfection (Figure 8). Cytoplasmic relocalization
of HIV-1 RNA occurred more quickly in transfected cells than
in cells stimulated with PHA (Figure 1B), reﬂecting the rapid
and robust expression of PTB upon transfection, compared
with slower upregulation following mitogen stimulation.
Taken together, these results indicate that PTB acts post-
transcriptionally in the nucleus to facilitate export of HIV-1
transcripts to the cytoplasm prior to virus production.
PTB Expression Is Sufficient to Reverse HIV-1 Latency and
Induce Production of Replication-Competent Virus
The studies described above show that the low levels of MS
HIV-1 RNA found in resting CD4
þ T cells from patients on
HAART are predominantly localized to the nucleus, and that
overexpression of PTB can facilitate export of these forms
and induce virion production. While it cannot be deﬁnitively
shown that the small subset of resting CD4
þ T cells harboring
replication-competent HIV-1 have similar patterns of RNA
localization and respond similarly to PTB, the above results
raise the possibility that overexpression of PTB might reverse
HIV-1 latency. Therefore, we analyzed the ability of PTB
overexpression to stimulate the production of replication-
competent HIV-1. The release of replication-competent virus
by PTB-transfected cells was measured directly in co-culture
experiments using CD4
þ T lymphoblasts from normal donors
to amplify virus released from infected cells. Virus outgrowth
was measured by supernatant levels of HIV-1 p24 antigen. For
cells transfected with PTB, and cultured without the addition
of blasts, and for mock-transfected cells co-cultured with
lymphoblasts, p24 levels remained below the limit of
detection in all patients studied (Figure 9). In contrast, when
PTB-transfected cells were co-cultured with lymphoblasts,
some wells showed readily detectable levels of supernatant
p24. Results with PTB-transfected cells were similar to those
seen when resting CD4
þ T cells were stimulated with the
mitogen PHA and then co-cultured with blasts, the standard
method for inducing latent HIV-1 [6]. Thus, PTB expression
allows the release of replication-competent virus from
latently infected cells.
Discussion
The molecular mechanism by which HIV-1 establishes a
latent infection in resting CD4
þ T cells is incompletely
understood. There are profound physiologic differences
Figure 6. PTB Localization in Transfected Primary Cells
Resting CD4
þT cells were mock-transfected or were transfected with the expression construct indicated on far left and stained as indicated on the top.
Cells were stained with DAPI (blue) and with antibodies to actin (green) and PTB (red). Immunofluorescence of transfected resting CD4
þ T cells
demonstrated strong nuclear localization of both PTB and PTB ser-ala (speckled pink/blue pattern in nucleus). Transfected cells are indicated with
arrows.
DOI: 10.1371/journal.ppat.0020068.g006
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RNA Trafficking and HIV Latencybetween resting and activated CD4
þ T cells [10,71–73], and it
is possible that the absence of virus production in latently
infected resting CD4
þ T cells is a natural consequence of
some of these differences. In fact, HIV-1 latency may not have
a single mechanism but rather may result from the combined
effects of incomplete blocks at multiple steps in the virus life
cycle. This study deﬁnes a previously unrecognized block in
virus gene expression that is unique to resting CD4
þ T cells
and that may be relevant to latency. Speciﬁcally, we show that
MS HIV-1 RNAs are retained in the nucleus of resting CD4
þT
cells. This block is particularly important because it is
positioned so as to interrupt a critical positive feedback loop
driven by HIV-1 Tat. We also show that overexpression of
nuclear forms of the RNA-binding protein PTB can overcome
this block by directly or indirectly promoting the nuclear
export of HIV-1 RNAs in a manner that does not induce T-
cell activation.
It is clear that HIV-1 latency is due at least in part to
mechanisms that affect transcriptional initiation and elonga-
tion [21,29–41,43–49]. Resting CD4
þ T cells from infected
individuals on HAART have much lower levels of full-length
HIV-1 RNA than do activated cells [49]. Interestingly, as
shown here and elsewhere [21], overexpression of Tat from a
non-HIV vector is sufﬁcient to induce virus production from
quiescent CD4
þ T cells. Since Tat acts downstream of
transcriptional initiation, the failure of resting CD4
þ T cells
from patients on HAART to produce virus may not be the
result of a general inaccessibility of integrated proviruses to
the transcriptional machinery. This conclusion is consistent
with recent studies of sites of HIV-1 integration [24,32,74,75],
Figure 7. Overexpression of PTB Does Not Increase in Total Intracellular
Concentrations of HIV-1 RNA
(A) Steady-state levels of HIV-1 RNA are not increased by overexpression
of PTB. Resting CD4
þ T cells (4 3 10
6) were transfected as described
above. 1 3 10
6 cells were isolated at various times post-transfection.
Total cellular RNA was isolated, and quantitative real-time RT-PCR was
performed using primers that detect total HIV-1 transcripts.
(B) PTB has no major effect on HIV-1 RNA stability. Resting CD4
þT cells (4
310
6) were transfected as described above. At 24 h post-transfection, a-
amanitin was added to cells to block de novo RNA synthesis. Total RNA
was isolated at given times and real-time RT-PCR was performed to
detect total HIV-1 RNAs.
DOI: 10.1371/journal.ppat.0020068.g007
Figure 8. PTB Expression Alters the Subcellular Distribution of HIV-1
RNAs in Primary Resting CD4
þ T Cells from patients on HAART
Nuclear (N), cytoplasmic (C), and total (T) RNA fractions were isolated
from mock-transfected (left) or PTB-transfected (right) resting CD4
þ T
cells 24 and 48 h post-transfection. RNA fractions were analyzed with
primers to detect US HIV-1 RNA.
DOI: 10.1371/journal.ppat.0020068.g008
Figure 9. PTB Expression Is Sufficient to Reverse HIV-1 Latency and to
Induce the Production of Replication-Competent Virus
Resting CD4
þ T cells from patients on HAART were transfected with
empty vector, or a PTB expression vector, or were stimulated with PHA.
Where indicated, cells were then co-cultured with uninfected, activated
CD4
þ T cells. Supernatant p24 levels were measured daily over a 2-wk
period. Peak p24 levels are shown for each condition. Results from two
representative patients are shown.
DOI: 10.1371/journal.ppat.0020068.g009
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genes. Taken together, these results indicate that some
initiation of HIV-1 transcription does occur in infected
resting CD4
þ T cells, and thus additional blocks operating
downstream of transcriptional initiation must contribute to
the absence of virion production.
One of the most important factors in the failure of infected
resting CD4
þ T cells to produce virions is likely to be the
premature transcriptional termination resulting from the
absence of Tat and associated cellular factors required for
processive transcription from the HIV-1 LTR [43–47]. Short
prematurely terminated transcripts can be demonstrated in
resting CD4
þ T cells from infected individuals [21,48,49].
However, although the majority of HIV-1 transcripts made in
resting cells terminate prematurely, improved methods have
allowed the detection of processive transcripts, including MS
HIV-1 RNAs, at extremely low levels in resting CD4
þ T cells
from patients on HAART [49]. Since these mRNAs should
give rise to the positive regulatory factors Tat and Rev, it is
important to understand why no positive feedback upregu-
lation of HIV-1 gene expression occurs.
To address this question, we examined the subcellular
localization of MS and US HIV-1 RNAs in resting CD4
þT cells
isolated from patients on HAART. Both species of HIV-1
RNA were localized to the nucleus of these cells. The ﬁnding
that MS HIV-1 mRNAs remain in the nucleus of resting CD4
þ
T cells has not been previously reported. This result is
important because it helps to explain why positive feedback
does not occur and deﬁnes an additional block at the post-
transcriptional level, which prevents expression of all viral
protein products. This post-transcriptional block does not
appear to be a global defect in resting CD4
þ T cells and is
speciﬁc to HIV-1 RNAs (Figure 1A).
To understand the nature of this block, a proteomic screen
for proteins binding MS HIV-1 RNA was performed using a
robust approach that successfully identiﬁed many proteins
previously known to bind HIV-1 RNA or to be general RNA-
binding proteins. PTB was studied as a potential positive
modulator of HIV-1 gene expression due to its ability to bind
MS HIV-1 RNA as well as its differential regulation in resting
and activated CD4
þ T cells. When overexpressed in resting
CD4
þ T cells from patients on HAART, PTB was sufﬁcient to
allow for high-level virus production without inducing
cellular stimulation. This effect was speciﬁc to PTB, as other
known HIV-1 RNA-binding proteins tested had no effect on
virus production. The effect was also speciﬁc to nuclear forms
of PTB as overexpression of PTBT, a cytoplasmic isoform,
had no effect on virus production.
The delineation of this export block required the analysis
of HIV-1 gene expression in primary CD4
þ T cells. Although
many elegant studies of latency have been carried out in
transformed cell lines, these cells do not fully recapitulate the
profoundly quiescent G0 state of the resting CD4
þT cells that
harbor latent HIV-1 in vivo. This block was not detected
previously because few studies have examined the localization
of HIV-1 RNAs in primary resting CD4
þT cells, cells in which
the levels of nuclear forms of PTB are low. Interestingly, the
block can be overcome by overexpression of Tat from a non-
HIV vector. In this situation, Tat-mediated upregulation of
transcriptional elongation allows virus production. Thus, it
may be that the nuclear export block observed in resting cells
is saturable, or that it can be overcome when levels of HIV-1
transcripts increase beyond a threshold value. Partial knock-
down of PTB in activated CD4
þ T cells did not affect virus
production. Thus, the clinical signiﬁcance of this ﬁnding is
likely to be in novel approaches for inducing virus gene
expression in resting CD4
þ T-infected cells (purging the
latent reservoir) rather than in inhibiting virus production by
fully activated cells.
Delineation of the mechanism for the nuclear retention of
MS HIV-1 RNA in resting CD4
þ T cells, and of the PTB
reversal of this block, remains to be accomplished and may
require the development of a more tractable system where
levels of HIV-1 RNA can be more easily modulated. The
nuclear retention of MS HIV-1 RNAs in resting CD4
þ T cells
may result from inefﬁcient transcription by RNA pol II
complexes that are not properly phosphorylated on the C-
terminal domain due to the absence of Tat and associated
host factors. This inefﬁcient transcription could result in
improper processing of the nascent HIV-1 mRNAs. Although
HIV-1 mRNAs in resting cells appear functional by sequence
analysis, assembly of downstream cellular RNA export factors
may be disrupted, resulting in nuclear retention of these
RNAs. PTB binds MS HIV-1 RNA and acts post-transcrip-
tionally to overcome this obstacle and therefore allows for
virus production. Whether the PTB-mediated reversal of
HIV-1 latency is a direct consequence of PTB binding to HIV-
1 RNA remains to be determined. Indeed, it is not possible to
assert from the results presented here that PTB reverses HIV-
1 latency by allowing the nuclear export of MS HIV-1 RNA. It
is clear that PTB overexpression can alter the distribution of
the majority of HIV-1 RNAs in resting CD4
þ Tc e l l
populations from patients on HAART. It is also clear that
PTB overexpression can induce latently infected cells in these
populations to release replication-competent virus. However,
it remains formally possible that these are two separate
effects. In other words, PTB may be altering the distribution
of HIV-1 RNAs in the majority of infected resting CD4
þ T
cells but reversing latency through a separate, as yet
unidentiﬁed mechanism. Despite this caveat, it remains clear
that PTB can induce the release of replication-competent
virus from resting CD4
þ T cells.
Efforts to eliminate a latent reservoir have focused on
strategies that induce some level of T-cell activation in order
to render cells permissive for HIV-1 gene expression [16–
21,23]. Because of the potential toxicities associated with non-
speciﬁc T-cell activation, there has been interest in ap-
proaches that would selectively induce viral gene expression
[20,21]. Thus, obtaining a greater understanding of the
mechanism of this PTB effect may contribute to the
development of strategies for targeting this critical viral
reservoir without inducing global T-cell activation.
Materials and Methods
Patients. Resting CD4
þ T cells were obtained from asymptomatic,
HIV-1-infected adults who had suppression of viremia to below 50
copies of HIV-1 RNA/ml on HAART for at least 6 mo.
RNA isolation and RT-PCR. Total RNA was isolated from 10
6
puriﬁed resting CD4
þT cells (described below) using the RNeasy Mini
Kit (Qiagen, Valencia, California, United States). To obtain nuclear
and cytoplasmic extracts, cells were lysed on ice for 5–10 min in lysis
buffer containing 10 mM TrisCl [pH 7.5], 140 mM NaCl, 5 mM KCl,
1% NP-40, 1,000 U/ml RNase inhibitor, and 1 mM DTT. Lysates were
centrifuged at 270 g for 5 min at 48 to pellet nuclei. Cytoplasmic
supernatants were removed and centrifuged at 13,000 g for 5 min to
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buffer for 5 min on ice and centrifuged at 270 g for 5 min. RNA was
then isolated from cytoplasmic and nuclear fractions using RNeasy.
All RNAs were DNase-treated with DNase I (Ampliﬁcation Grade,
Invitrogen, Carlsbad, California, United States). RT-PCR was per-
formed as described previously using hemi-nested PCR primer sets
US, E2, and E5 [49]. All RT-PCR experiments included control
reactions set up without the addition of RT, as well as no template
controls. All such controls were negative. Real-time RT-PCR was
performed using the Platinum Quantitative RT-PCR ThermoScript
One-Step System (Invitrogen) according to the manufacturer’s
protocol. Primers and probe for quantitative RT-PCR were as follows:
QPCR LTR39:5 9 TAAAAGGGTCTGA-GGGATCTCTAGTT39, QPCR
LTR59:5 9 GCCTCAATAAAGCTTGCCTTGA39, probe: 59 FAM-
AGTCACACAACAGACGGGCACACACTACTT-BlackHole Quench-
er1–39. Probes were obtained from Biosource International. The
quantitative real time RT-PCR has a limit of detection of 10–100
copies. The semi-quantitative method has a limit of detection of ;10
copies.
In vitro HIV-1 RNA-binding assays. MS HIV-1 RNA was cloned
from RNA isolated from patient PBMCs (peripheral blood mono-
nuclear cells). Reverse transcribed HIV-1 RNA containing exons 1, 5,
and 7 was cloned into pSP64 Poly(A) (Promega, Madison, Wisconsin,
United States). MS HIV-1 RNA was produced by in vitro transcription
using the RiboMAXe Large Scale RNA Production System (Promega)
according to manufacturer’s protocol. The resulting RNA was
incubated with an equimolar amount of a biotinylated oligo-dT
probe coupled to streptavidin magnetic particles (Roche, Basel,
Switzerland). The RNA-coated beads were incubated with lyastes (50
lg) of puriﬁed resting or activated CD4
þ T cells. RNA-binding
proteins were identiﬁed by PAGE MS/MS using the mass spectrom-
etry facility of Dr. Bill Lane at Harvard Medical School. For
recombinant protein binding assays, 50 ng of protein was used.
Recombinant proteins. cDNA encoding full-length PTB isoform 1
(kind gift of S. Bouyain and B. Geisbrecht) was cloned into the pT7
vector, which encodes an N-terminal poly-histidine tag followed by a
Tobacco Etch Virus cleavage site. Recombinant protein was ex-
pressed in Rosetta pLysS expression hosts (EMD Biosciences), and
soluble protein was puriﬁed using nickel-loaded Chelating Fast Flow
resin (Amersham Biosciences, Little Chalfont, United Kingdom). The
partially puriﬁed protein was cleaved using recombinant TEV
protease (Invitrogen), and fully cleaved protein from a reverse IMAC
puriﬁcation was further puriﬁed to near homogeneity using a
Superdex S-200 gel ﬁltration column (Amersham Biosciences).
Protein concentration was determined using the UV spectroscopy
at 278 nm.
Antibodies, Western blots, and immunoﬂuorescence. Anti-PTB was
obtained from Zymed (San Francisco, California, United States). For
Western blots, a 1:350 dilution of antibody was used, and for
immunoﬂuorescence, a 1:250 dilution was used. Both La and
hnRNPA1 antibodies were used at a concentration of 0.5 lg/ml for
Western blots. 20 lg of total protein were loaded per lane for
Western blots. For immunoﬂuorescence, AlexoFluor596 (Molecular
Probes, Eugene, Oregon, United States) was used as a secondary
reagent according to manufacturer’s protocol. OregonGreen 488
phalloidin was used for actin staining according to manufacturer’s
protocol (Molecular Probes). Nuclear staining was performed with
DAPI (Molecular Probes) using ProLong Gold antifade reagent.
Images were taken using a Perkin Elmer (Wellesley, Massachusetts,
United States) UltraVIEW Spinning Disk Confocal Microscope.
T-cell puriﬁcation and transfections. Resting CD4
þ T cells were
isolated through a two-step puriﬁcation procedure as previously
described [6,49]. To obtain activated CD4
þ T cells, Ficoll-puriﬁed
PBMCs were stimulated with PHA for 3 d, and CD4
þ T cells were
positively selected using the Dynal (Oslo, Norway) CD4
þ selection kit.
Transfections were performed using an Amaxa Nucleofector. 2–4 3
10
6 puriﬁed CD4
þ T cells were re-suspended in 100 ll/10
6 cell in
nucleofector solution and transfected using program U-14. The
number of cells used depended on the number of cells obtained after
puriﬁcation. Cells were cultured in 1.5 ml medium after transfection.
For a given patient, the number of cells used was identical for each
condition. For each transfection, 2.5 lg of empty vector or plasmid
with PTB, PTBS-A, PTBT, or pcDNA-TAT-86 was transfected with 2.5
lg of plasmid phMGFP (Promega). GFP expression served as a control
for transfection efﬁciency. For RNA-turnover experiments, a-
amanitin was added to medium at a ﬁnal concentration of 50 lg/ml
24 h after transfection. Total RNA was isolated at various time points
after a-amanitin addition. PTB and PTBT were cloned
from PBMC cDNA using the following primers:
59ACGCGTCGACAATGGACGGCATTGTCCCAGATATAGCC39 and
59ATAGAATGCGGCCGCCTAGATGGTGGACTTGGAGAAGG39.
PCR products were cloned using SalI and NotI restriction sites into
the pCI-neo mammalian expression vector (Promega). PTB ser-ala
was made by direct mutagenesis of serine16 to alanine in the PTB
expression vector. pcDNA-TAT-86 was a gift from Dr. Avi Nath
(Johns Hopkins University, Baltimore, Maryland, United States).
T-cell co-culture. To isolate replication competent viruses from
latently infected cells after PTB transfection, transfected cells were
co-cultured with CD4
þ lymphoblasts from uninfected donors as
described previously [6]. Resting CD4
þ T cells were isolated from
patients on HAART and transfected as described above. At 24 h after
transfection, lymphoblasts were added to each well at a ratio of 2:1 to
amplify virus released from latently infected cells. In control wells,
untransfected resting CD4
þ T cells were activated with PHA and co-
cultured with lymphoblasts as previously described [6]. Supernatants
were sampled every day over a 2-wk period, and levels of p24 antigen
were measured by ELISA.
Supporting Information
Figure S1. Proteomic Screen for MS HIV-1 RNA-Binding Proteins
(A) Schematic of in vitro-transcribed MS HIV-1 RNA used in binding
assays. This RNA contains exons 1, 5, and 7. (B) Silver stain of MS
HIV-1 RNA-binding proteins in CD4
þT cells. Bands that decreased in
intensity with increasing molar equivalents of competitor RNA (non-
biotinylated MS HIV-1 RNA) were analyzed (arrows).
Found at DOI: 10.1371/journal.ppat.0020068.sg001 (184 KB DOC).
Figure S2. Effect of siRNA Knockdown of PTB on Virus Production
by Infected CD4
þ T Lymphoblasts
(A) Semi-quantitative RT-PCR of full-length PTB in cells transfected
with a non-targeting siRNA or a siRNA directed against PTB. Semi-
quantitative RT-PCR for GAPDH served as an input control. (B)
Knockdown of PTB in activated CD4
þ T cells had no effect on HIV-1
production. Resting CD4
þ T cells from patients on HAART were
activated with PHA and then transfected 48 h post-stimulation with a
non-targeting siRNA or a siRNA directed against PTB. Cells were
washed every 24 h and supernatants were analyzed for viral load 72 h
post-transfection.
Found at DOI: 10.1371/journal.ppat.0020068.sg002 (36 KB DOC).
Accession Numbers
The National Center for Biotechnology (NCBI) (http://www.ncbi.nlm.
nih.gov) accession number for polypyrimidine tract binding protein
(PTB) is NM_002819.3.
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